{ "items": [ "\n\n
\n \n\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n13 April 2021
\n \n \n \nTingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.
\n \n\n \n \n13 April 2021
\n \n \n \n\n \n \n12 April 2021
\n \n \n \n\n \n \n12 April 2021
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n12 April 2021
\n \n \n \nInhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.
\n \n\n \n \n12 April 2021
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n7 April 2021
\n \n \n \nToday, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n7 April 2021
\n \n \n \nOne in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n7 April 2021
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n7 April 2021
\n \n \n \nA new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with \u00a32 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.
\n \n\n \n \n1 April 2021
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n31 March 2021
\n \n \n \nBereaved relatives described the ongoing pain of being absent at the end of a loved-one's life. Many had not seen their relative for weeks or months due to the pandemic. Opportunities must be prioritised for essential connections between families at end-of-life care.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n31 March 2021
\n \n \n \nA survey led by Nuffield Department of Population Health's Health Economics Research Centre has found that most people in high-income countries support donating some of their country\u2019s COVID-19 vaccine supplies to low-income nations who would otherwise struggle to gain access.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n30 March 2021
\n \n \n \nA new study from the Department of Physiology, Anatomy & Genetics (DPAG) has shed light on a key regulatory step in the initiation and progression of Abdominal Aortic Aneurysm by revealing the protective role of a previously little known small protein.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n29 March 2021
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n29 March 2021
\n \n \n \nAn international research team led by Oxford University scientists has developed a portable test for antibodies that fight the novel coronavirus that causes COVID-19.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n29 March 2021
\n \n \n \nA new study has found that 99% of people generate a robust immune response against COVID-19 after just one dose of the Pfizer vaccine, and that after two doses levels of protection were even stronger.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n29 March 2021
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n26 March 2021
\n \n \n \nThe University of Oxford is launching a study investigating the delivery of the ChAdOx1 nCoV-19 coronavirus vaccine using a nasal spray.
\n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n25 March 2021
\n \n \n \nOur partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.
\n \n\n \n \n